BiotchPharma

Early access, named patient supply and market entry for Turkiye.

BiotchPharma supports innovative pharmaceutical and biotech companies with Early Access Programs, Named Patient Programs, Managed Access, clinical-trial interface, market access, distributorship and launch preparation.

10-15 years drug development realityEAP / NPP / MAP access pathwaysTurkiye local market execution

Leave No One Behind

Access to promising medicines when patients and physicians cannot wait.

BiotchPharma’s public service model is built around a clear principle: promising medicines should reach eligible patients through responsible, documented and locally managed pathways. This is especially important in rare, ultra-rare and life-threatening diseases where formal registration can lag behind urgent clinical need. For drug developers, BiotchPharma connects early access, clinical development awareness, institutional coordination, distribution readiness and commercial launch preparation in one local partner model.

Official service focus

  • Rare diseases, orphan drugs and specialty medicines
  • Early Access, Named Patient, Managed Access and Expanded Access
  • Compassionate Use, Post-Trial Access and Named Patient Import
  • Market access, sales, marketing, KOL and KAM execution
  • Local representation, distributorship and Turkiye launch preparation

Access Model

Structured routes before, during and after commercialization.

BiotchPharma positions access programs as a bridge between scientific innovation, physician need and Turkish healthcare pathways.
01

Early Access Programs

Program design, sponsor alignment, physician communication, access criteria, documentation and follow-up for medicines not yet routinely available.
02

Named Patient Programs

Patient-level supply coordination under physician responsibility, including Named Patient Import and urgent product availability tracking.
03

Managed and Expanded Access

Structured local access rules, stakeholder mapping, reporting expectations and operational control for eligible patients.
04

Post-Trial Access

Continuity planning for patients who benefited from trial treatment and need responsible access after study completion.

Clinical Research Interface

Clinical trials remain the strongest evidence path. Access programs protect continuity when trials are not enough.

BiotchPharma supports feasibility, study center and clinic selection, patient identification, central monitoring, data entry, SMO services, patient supply and clinical research archive coordination. When a patient cannot enter a trial, when a trial has ended, or when a medicine is not yet commercially available, BiotchPharma helps sponsors and physicians evaluate responsible access options.

Institutional Coordination

Local execution across the real healthcare pathway.

BiotchPharma coordinates with the Turkish Ministry of Health, TITCK, Turkish Pharmacists Association, hospitals, clinics, CROs, depots, customs and local supply stakeholders. This local control helps developer companies enter Turkiye with stronger documentation, clearer reporting and fewer operational surprises.

Market Entry

From first access signal to full local launch preparation.

Designed for biotech, specialty pharma and orphan-drug developers that need a serious local partner before building a full Turkiye organization.
01

Assess

Product profile, unmet need, clinical centers, patient pathway, physician interest and market opportunity.
02

Prepare

EAP, NPP, MAP, Named Patient Import, Compassionate Use, pricing context and regulatory pathway readiness.
03

Supply

Distributor, importer, depot, pharmacy, cold-chain, customs and documentation preparation.
04

Launch

KOL engagement, advisory boards, congress participation, launch meetings, KAM planning, sales and marketing.

Specialist Capabilities

Commercial and medical operations for high-need therapies.

BiotchPharma supports companies developing or commercializing niche, orphan, unlicensed and licensed medicines.

Therapeutic focus

Rare diseases, ultra-rare diseases, oncology, hematology, genetic diseases, metabolic diseases, cardiology, neurology and specialty care.

Medical network

KOL mapping, advisory boards, scientific boards, physician segmentation and disease-area communication.

Commercial readiness

Country management, branch preparation, distributor coordination, market access, reimbursement readiness and value communication.

Field execution

Sales team setup, Key Account Management, congress activities, launch meetings and brand-growth execution.

Reporting discipline

Program tracking, sponsor updates, adverse-event routing, supply status and local process visibility.

Partnership models

Licensing, co-marketing, co-promotion, early access collaboration, distributorship and strategic business development.

Therapeutic Focus

Built for products where access, trust and timing matter.

Rare DiseasesOrphan DrugsOncologyHematologyGenetic DiseasesMetabolic DiseasesNeurologyCardiologySpecialty Care

Send Files To BiotchPharma

Share product, clinical or partnership details with the BiotchPharma team.

Use the secure message box below to attach a product dossier, clinical synopsis, presentation or partnership file. Messages and files are delivered to fatih.aktas@biotchpharma.com.

Secure Enquiry

Send a message with attachment

Your request will be routed to fatih.aktas@biotchpharma.com.

PDF, DOCX, XLSX, PPTX, JPG, PNG or ZIP up to 10 MB
Accepted file types: PDF, DOC, DOCX, XLS, XLSX, PPT, PPTX, JPG, PNG and ZIP. Maximum size: 10 MB.

By sending this form, you authorize Biotech Group to review your enquiry and contact you about the requested service.

Partner With BiotchPharma

Build your Turkiye access and commercialization pathway with a specialist local partner.

For Early Access, Named Patient Programs, orphan drugs, market access, sales and marketing, contact the BiotchPharma business development team.